Allergan Aesthetics has secured Health Canada approval for Boey, a rapid-onset, short-duration neuromodulator indicated for glabellar lines. The approval represents a significant step forward for AbbVie's next-generation toxin platform, though U.S. FDA status remains unconfirmed.
Boey is engineered to onset faster than Botox (typically 3–5 days versus 7–14 days) while maintaining a shorter duration of effect—a profile designed to appeal to patients seeking flexibility and practitioners seeking faster patient satisfaction. The mechanism involves a proprietary formulation and delivery system distinct from traditional botulinum toxin A preparations. Health Canada's approval validates the safety and efficacy profile and signals likely FDA submission in the near term.